ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 258 filers reported holding ACCELERON PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.78 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $923,339,000 | +38.8% | 5,365,133 | +1.2% | 0.09% | +40.3% |
Q2 2021 | $665,073,000 | -8.5% | 5,299,812 | -1.1% | 0.06% | -15.1% |
Q1 2021 | $726,640,000 | +7.0% | 5,358,304 | +0.9% | 0.07% | +4.3% |
Q4 2020 | $679,331,000 | +16.2% | 5,309,766 | +2.2% | 0.07% | +2.9% |
Q3 2020 | $584,635,000 | +30.5% | 5,195,373 | +10.5% | 0.07% | +21.4% |
Q2 2020 | $447,971,000 | +22.8% | 4,702,119 | +15.9% | 0.06% | -3.4% |
Q1 2020 | $364,688,000 | +100.4% | 4,057,954 | +18.2% | 0.06% | +141.7% |
Q4 2019 | $182,004,000 | +34.9% | 3,432,743 | +0.5% | 0.02% | +26.3% |
Q3 2019 | $134,944,000 | -13.0% | 3,415,437 | -9.5% | 0.02% | -13.6% |
Q2 2019 | $155,041,000 | -25.9% | 3,774,113 | -16.0% | 0.02% | -29.0% |
Q1 2019 | $209,351,000 | -4.2% | 4,495,413 | -10.4% | 0.03% | -16.2% |
Q4 2018 | $218,432,000 | -19.8% | 5,015,667 | +5.4% | 0.04% | -7.5% |
Q3 2018 | $272,416,000 | +30.9% | 4,760,028 | +10.9% | 0.04% | +25.0% |
Q2 2018 | $208,189,000 | +46.8% | 4,290,792 | +18.3% | 0.03% | +39.1% |
Q1 2018 | $141,863,000 | +5.0% | 3,628,222 | +13.9% | 0.02% | +4.5% |
Q4 2017 | $135,162,000 | +14.8% | 3,184,770 | +1.0% | 0.02% | +10.0% |
Q3 2017 | $117,693,000 | +0.7% | 3,153,619 | -18.0% | 0.02% | -4.8% |
Q2 2017 | $116,908,000 | +13.1% | 3,846,907 | -1.5% | 0.02% | +10.5% |
Q1 2017 | $103,326,000 | +8.9% | 3,903,525 | +5.0% | 0.02% | 0.0% |
Q4 2016 | $94,855,000 | -20.2% | 3,716,879 | +13.2% | 0.02% | -20.8% |
Q3 2016 | $118,876,000 | +11.3% | 3,284,766 | +4.5% | 0.02% | +4.3% |
Q2 2016 | $106,840,000 | +37.4% | 3,144,199 | +6.7% | 0.02% | +35.3% |
Q1 2016 | $77,775,000 | -45.6% | 2,947,139 | +0.6% | 0.02% | -43.3% |
Q4 2015 | $142,841,000 | +83.6% | 2,929,479 | -6.3% | 0.03% | +76.5% |
Q3 2015 | $77,813,000 | -21.9% | 3,125,001 | -0.7% | 0.02% | -15.0% |
Q2 2015 | $99,591,000 | -17.6% | 3,147,643 | -0.8% | 0.02% | -20.0% |
Q1 2015 | $120,815,000 | -9.1% | 3,174,335 | -6.9% | 0.02% | -10.7% |
Q4 2014 | $132,907,000 | +35.9% | 3,411,375 | +5.5% | 0.03% | +33.3% |
Q3 2014 | $97,828,000 | -12.0% | 3,235,055 | -1.1% | 0.02% | -12.5% |
Q2 2014 | $111,141,000 | +74.7% | 3,271,727 | +77.4% | 0.02% | +71.4% |
Q1 2014 | $63,613,000 | +65.3% | 1,843,843 | +89.8% | 0.01% | +250.0% |
Q4 2013 | $38,476,000 | – | 971,600 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |